ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The specialty drug firm Shuttle Pharmaceuticals has picked TCG GreenChem, the US subsidiary of India’s TCG Lifesciences, to manufacture ropidoxuridine, its lead drug candidate. TCG, with facilities in Ewing Township, New Jersey, and Richmond, Virginia, will also perform process R&D and optimization. Shuttle is preparing for Phase 2 clinical trials of ropidoxuridine as a sensitizer that reduces the side effects of cancer radiation therapy.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X